Imidazole derivatives and their use for modulating the GABA
This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are of the general formula (I) and include any of its stereoisomers, any mixture of its stereoisomers, and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA A receptor complex, and in particular for combating anxiety and related diseases.
1. A compound of the general formula (I):
any of its stereoisomers or any mixture of its stereoisomers,
or a pharmaceutically acceptable salt thereof,
wherein
R 1 represents an oxadiazolyl;
which oxadiazolyl is optionally substituted with one or more substituents independently selected from the group consisting of:
halo, hydroxy, hydroxyalkyl, R a R b N—, R a R b N-alkyl, cyano, nitro, trifluoromethyl, trifluoromethoxy, alkoxy, cycloalkoxy, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, and alkynyl;
wherein R a and R b independent of each other are hydrogen or alkyl;
R 2 represents
an aryl or heteroaryl group;
which aryl or heteroaryl group is optionally substituted with one or more substituents independently selected from the group consisting of:
halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, alkoxy, R e —(C═O)—, R e —O—(C═O)— and alkyl;
wherein R e and R f independent of each other are hydrogen or alkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R 1 represents an oxadiazolyl;
which oxadiazolyl is optionally substituted with one or more alkyl.
3. The compound of claim 1 , which is selected from the group consisting of
5-(1-Biphenyl-3-yl-1H-imidazol-4-yl)-3-methyl-[1,2,4]oxadiazole;
5-[1-(2′,5′-Dimethoxy-biphenyl-3-yl)-1H-imidazol-4-yl]-3-methyl-[1,2,4]oxadiazole;
5-[1-(2′-Methoxy-biphenyl-3-yl)-1H-imidazol-4-yl]-3-methyl-[1,2,4]oxadiazole;
5-[1-(5′-Fluoro-2′-methoxy-biphenyl-3-yl)-1H-imidazol-4-yl]-3-methyl-[1,2,4]oxadiazole;
5-[1-(2′-Ethyl-biphenyl-3-yl)-1H-imidazol-4-yl]-3-methyl-[1,2,4]oxadiazole;
5-[1-(2′-Ethoxy-biphenyl-3-yl)-1H-imidazol-4-yl]-3-methyl-[1,2,4]oxadiazole;
3-Methyl-5-[1-(2′-trifluoromethoxy-biphenyl-3-yl)-1H-imidazol-4-yl]-[1,2,4]oxadiazole;
3-Methyl-5-[1-(2′-acetyl-biphenyl-3-yl)-1H-imidazol-4-yl]-[1,2,4]oxadiazole;
3-Methyl-5-[1-(2′-fluoro-biphenyl-3-yl)-1H-imidazol-4-yl]-[1,2,4]oxadiazole;
2-Fluoro-5-{3-[4-(3-methyl-[1,2,4]oxadiazol-5-yl)-imidazol-1-yl]-phenyl}-pyridine;
3-Methyl-5-[1-(2′-cyano-biphenyl-3-yl)-1H-imidazol-4-yl]-[1,2,4]oxadiazole; and
3-Methyl-5-[1-(2′-carboxylic acid-biphenyl-3-yl)-1H-imidazol-4-yl]-[1,2,4]oxadiazole;
or any of its stereoisomers or any mixture of its stereoisomers,
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition, comprising a therapeutically effective amount of a compound of claim 1 , any of its stereoisomers or any mixture of its stereoisomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.